JPMorgan Predicts Boom in Obesity Drug Sales, Tipping Eli Lilly as Winner

JPMorgan forecasts a significant increase in direct-to-consumer sales for obesity drugs, identifying Eli Lilly as the primary beneficiary due to its 'best-in-class' GLP-1 status.

25 Feb, 15:36 — 25 Feb, 15:36

Post Share

Sources

Showing 1 of 1 sources

cnbcMostly Factual46d ago

Direct-to-consumer sales for obesity drugs are about to boom. JPMorgan sees Eli Lilly as big winner

Thanks to its “best-in-class” status, the bank believes the company will be the winner from a growing GLP-1 patient base.

Read full article →

PERSPECTA

PERSPECTA

JPMorgan Predicts Boom in Obesity Drug Sales, Tipping Eli Lilly as Winner

Sources

Direct-to-consumer sales for obesity drugs are about to boom. JPMorgan sees Eli Lilly as big winner

Related Stories

Amazon's First Customer Receipt Goes Viral, Bezos and Musk React

Philippines Energy Secretary Confirms Diesel Cargo Arrival Amid Petronas Denial

Philippine President Marcos Urges Unity, Warns Against Hoarding Amid Energy Crisis

Marcos to decide on fuel excise tax cut or suspension by April 13

PERSPECTA